Analyst firms · Morgan Stanley · NEO
Morgan Stanley NEO price target and rating history
NeoGenomics Inc. (NEO) · Health Care
Morgan Stanley rates NeoGenomics Inc. (NEO) Equal-Weight with a $29 price target, as of its latest action on Feb 24, 2022. It has published 3 rating actions on NEO since August 2021, including 0 upgrades and 1 downgrade.
- Current rating
- Equal-Weight
- Price target
- $29
- Median target, all firms
- Too few
- Actions on NEO
- 3
Morgan Stanley price target on NEO
Every Morgan Stanley rating on NEO
- Feb 24, 2022
- Nov 5, 2021
- Aug 9, 2021
How other firms rate NEO
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BTIG | Buy | $28 | Oct 6, 2026 |
| Leerink Partners | Outperform | $25 | Apr 29, 2026 |
Questions about Morgan Stanley and NEO
- What is Morgan Stanley's price target for NEO?
- Morgan Stanley's latest stated price target for NeoGenomics Inc. (NEO) is $29, from its action on Feb 24, 2022.
- What is Morgan Stanley's rating on NEO?
- Morgan Stanley rates NEO Equal-Weight, a neutral rating, as of Feb 24, 2022.
- When did Morgan Stanley last change its view on NEO?
- On Feb 24, 2022, Morgan Stanley cuts its price target to $29 from $30, keeps Equal-Weight.
More NEO rating histories
All Morgan Stanley ratingsNEO news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.